Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAK Inhibitors for Refractory ICI-related Dermatitis in Solid Tumors
NCT07530224Phase 2Not yet recruiting
- Sponsor
- Hangzhou Cancer Hospital
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of upadacitinib, tofacitinib oral solution in drug-induced dermatitis, sponsored by Hangzhou Cancer Hospital. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
upadacitinibtofacitinib oral solution
03
Conditions
drug-induced dermatitis
Beyond the preview
Go deeper on NCT07530224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07530224.